Ofloxacin Bristol Laboratories

Ofloxacin, the active ingredient in Ofloxacin Bristol Laboratories, is a fluoroquinolone antibiotic presented as a strength/form for oral use. It treats bacterial infections in adults and children when prescribed by a healthcare professional.

GNH USA supplies Ofloxacin Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ofloxacin is a broad‑spectrum antibacterial that acts on Gram‑negative and Gram‑positive organisms in several infection pathways. - Urinary tract infection: helps eradicate the causative bacteria and relieve symptoms. - Respiratory tract infection: reduces bacterial load in conditions such as acute exacerbations of chronic bronchitis. - Skin and soft‑tissue infection: assists in clearing infection and promoting wound healing.

Adverse reactions to Ofloxacin may vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain

Serious or Rare Side Effects: - Tendon rupture or inflammation - Peripheral neuropathy - Severe skin reactions such as Stevens‑Johnson syndrome - QT interval prolongation - Clostridioides difficile‑associated colitis

When using Ofloxacin, consider the following safety measures: - Renal impairment: adjust dose based on renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of tendon disorders: avoid if previous tendon injury related to fluoroquinolones. - Concomitant QT‑prolonging drugs: monitor cardiac rhythm. - Pregnancy and lactation: only use if clearly needed. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ofloxacin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: may reduce absorption. - Warfarin: may increase anticoagulant effect and bleeding risk. - Cyclosporine: increased risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Theophylline: may increase plasma concentrations. - Oral hypoglycaemic agents: may cause abnormal glucose levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system effects.